The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Alzheimer’s Drugs Market At The End Of The 2026–2030 Forecast Period?
The alzheimer’s drugs market has shown substantial growth in recent years. Its size is expected to increase from $10.09 billion in 2025 to $10.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.9%. Historically, this expansion has been driven by an expanding elderly population, a rise in the prevalence of alzheimer’s disease, greater awareness regarding dementia care, a scarcity of treatment options in its early stages, and advancements in neuroscience research.
The alzheimer’s drugs market is projected to experience substantial growth in the upcoming years. Its valuation is anticipated to reach $15.4 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.8%. This expansion during the forecast period can be attributed to progress in precision medicine, the incorporation of AI in drug development, the enlargement of healthcare infrastructure, governmental backing and financial support for dementia research, and the rise of digital health monitoring solutions. Significant trends foreseen in the forecast period include the evolution of personalized alzheimer’s therapy, innovations in neuroprotective drugs, improved early diagnosis and screening solutions, the development of combination and multi-target drugs, and advanced patient adherence and monitoring solutions.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp
What Primary Drivers Are Shaping The Development Of The Alzheimer’s Drugs Market?
The increasing occurrence of Alzheimer’s disease is anticipated to drive expansion in the Alzheimer’s drugs market in the future. This neurological condition progressively deteriorates, leading to both cerebral atrophy and neuronal demise. Medications for Alzheimer’s disease are used to address memory deficits, challenges with thinking and reasoning, and difficulties with everyday living. These treatments can enhance an individual’s quality of life and support their autonomy. For example, data from May 2024, published by the Alzheimer’s Association, a US-based nonprofit organization focused on Alzheimer’s care, support, and research, revealed an increase in Americans aged 65 and above diagnosed with Alzheimer’s dementia, climbing from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the expanding incidence of Alzheimer’s disease is fueling the development of the Alzheimer’s drugs market.
What Segment Types Make Up The Alzheimer’s Drugs Market?
The alzheimer’s drugs market covered in this report is segmented –
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Which Market Trends Are Creating New Opportunities In The Alzheimer’s Drugs Market?
Leading companies in the Alzheimer’s drugs market are developing innovative products, such as amyloid plaque-targeting therapy, to advance treatment options and improve patient outcomes. Amyloid plaque-targeting therapy is a treatment approach for Alzheimer’s disease that focuses on reducing or preventing the accumulation of amyloid-beta plaques in the brain. For instance, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, secured approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency for protecting public health. Kisunla (donanemab-azbt) is the first and only amyloid plaque-targeting therapy specifically for early symptomatic Alzheimer’s disease. It functions by assisting the body in clearing excess amyloid plaques from the brain, which are linked to cognitive decline in Alzheimer’s patients. Kisunla is administered as an intravenous infusion every four weeks. The initial dosing regimen involves 700 mg for the first three doses, followed by 1400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease, provided they have confirmed amyloid pathology.
Who Are The Key Players Driving Competition In The Alzheimer’s Drugs Market?
Major companies operating in the alzheimer’s drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.
Read the full alzheimer’s drugs market report here:
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
How Does The Alzheimer’s Drugs Market Perform Across Major Global Regions?
North Americawas the largest region in the Alzheimer’s drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer’s drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Alzheimer’s Drugs Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp
Browse Through More Reports Similar to the Global Alzheimer’s Drugs Market 2026, By The Business Research Company
Alzheimers Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Alzheimers Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model